All treated AML patients in both the original and expansion cohorts through January 17, 2025 remain in complete remission. The original cohort of AML patients has reached a median CR of 23.3 months, ...
A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled “A case report of donor cell–derived ...
Omeros Corporation (Nasdaq: OMER) today announced two presentations that will be featured at the 2025 Tandem Meetings – the ...
Hematopoietic stem cell transplantation (HSCT) is a vital treatment for both malignant and non-malignant disorders in pediatric patients.
Patients with childhood and young adult cancer have an increased long-term risk for diabetes, noted as early as 10 years ...
Orca Bio announces it met the primary endpoint in its pivotal Phase 3 clinical study for its lead allogeneic T-cell immunotherapy, Orca-T.
The Metachromatic Leukodystrophy Initiative (MLDi) critically responds to the findings of Zhang et al. on lentivirus-modified ...
IN8bio (INAB) announced new clinical data from the ongoing Phase 1 investigator-sponsored trial of INB-100, an allogeneic gamma-delta T cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback